News | August 27, 2021
Pharma continues to attract PE investments: Care Ratings
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Domestic business was up 41.9% YoY and 27.7% QoQ
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Goal of providing 12-month internship opportunities for qualified students
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Subscribe To Our Newsletter & Stay Updated
